According to Farshid Guilak, Ph.D., senior member of the research team and director of orthopedic research at Duke, these findings should theoretically help physicians repair knee joints damaged by injury or osteoarthritis.
There already is a drug that blocks the effects of TNF that is used widely and effectively in patients with rheumatoid arthritis, the form of the disease caused by bodys own immune system attacking the joint, Guilak said. Another drug also exists that blocks IL-1 that is being used for rheumatoid arthritis and is currently undergoing clinical trials for osteoarthritis.
These drugs are administered to the entire body. However, the key to the possible new approach would be to deliver these agents directly into the site of meniscus damage, Guilak said.
'/>"/>
| Contact: Richard Merritt Merri006@mc.duke.edu 919-660-1309 Duke University Medical Center Source:Eurekalert |